Reporter brief
Sirolimus Versus AntiVEGF for Wet AMD
What happened
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- No effect sizes or specific outcomes reported, preventing assessment of whether sirolimus offers meaningful clinical benefit over anti-VEGF
- Single-site design limits generalizability to broader populations with treatment-resistant wet AMD
- Phase 2 status indicates this was a preliminary efficacy and safety study, not a definitive effectiveness trial
Study design and sample
Rct; Human.
Subjects with wet Age-Related Macular Degeneration (wet AMD) with persistent intraretinal or subretinal edema due to neovascular AMD despite previous AntiVEGF treatment
- Design
- Rct
- Sample
- —
- Journal
- Maturi, Raj K., M.D., P.C.
- Published
- Jun 22, 2017
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.